Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Pyranyl aryl methyl benzoquinolinone M1 receptor positive allosteric modulators
US9260418B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9260418-B2 |
| Application number | US-201414470080-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 27, 2014 |
| Priority date | Aug 31, 2009 |
| Publication date | Feb 16, 2016 |
| Grant date | Feb 16, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of therapeutically treating Alzheimer's disease in a patient in need thereof, wherein therapeutically treating consists of inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the disease, comprising administering to the patient a therapeutically effective amount of a compound of formula I: or…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9260418B2 cover?
- The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical composition…
- Who is the assignee on this patent?
- Merck Sharp & Dohme
- What technology area does this patent fall under?
- Primary CPC classification C07D405/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).